Michael Gilbert

Michael Gilbert

Auto-generated profile, based on publicly available information

Michael Gilbert

Independent Researcher, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2015
Verified
Journal Article
Closed access
EWEliza Wheeler
Eliza Wheeler
TJT. Stephen Jones
T. Stephen Jones
MGMichael K. Gilbert
Michael K. Gilbert
PDPeter J. Davidson
Peter J. Davidson

1 March 2020 in International Journal of Drug Policy
Verified
Journal Article
Open access
TGTraci C. Green
Traci C. Green
JPJu Nyeong Park
Ju Nyeong Park
MGMichael Gilbert
Michael Gilbert
MMMichelle McKenzie
Michelle McKenzie
ESEric Struth
Eric Struth
SSSusan G. Sherman
Susan G. Sherman
Fentanyl has caused rapid increases in US and Canadian overdose deaths, yet its presence in illicit drugs is often unknown to consumers. This study examined the validity in identifying the presence of fentanyl of three portable devices that could be used in providing drug checking services and drug supply surveillance: fentanyl test strips, a hand-held Raman Spectrometer, and a desktop Fourier-Transform Infrared Spectrometer. In Fall 2017, we first undertook an assessment of the limits of detection for fentanyl, then tested the three devices' sensitivity and specificity in distinguishing fentanyl in street-acquired drug samples. Utilizing test replicates of standard fentanyl reference material over a range of increasingly lower concentrations, we determined the lowest concentration reliably detected. To establish the sensitivity and specificity for fentanyl, 210 samples (106 fentanyl-positive, 104 fentanyl-negative) previously submitted by law enforcement entities to forensic laboratories in Baltimore, Maryland, and Providence, Rhode Island, were tested using the devices. All sample testing followed parallel and standardized protocols in the two labs. The lowest limit of detection (0.100 mcg/mL), false negative (3.7%), and false positive rate (9.6%) was found for fentanyl test strips, which also correctly detected two fentanyl analogs (acetyl fentanyl and furanyl fentanyl) alone or in the presence of another drug, in both powder and pill forms. While less sensitive and specific for fentanyl, the other devices conveyed additional relevant information including the percentage of fentanyl and presence of cutting agents and other drugs. Devices for fentanyl drug checking are available and valid. Drug checking services and drug supply surveillance should be considered and researched as part of public health responses to the opioid overdose crisis.

1 October 2016 in JAMA Internal Medicine
Verified
Journal Article
Closed access
PDF file
TGTraci C. Green
Traci C. Green
MGMichael Gilbert
Michael Gilbert
The steep recent increase in overdose deaths and near-deaths nationwide involving fentanyl signals a new chapter in the epidemic of opioid use. Throughout the U

1 February 2017 in JMIR Public Health and Surveillance
Verified
Journal Article
Open access
LALaurie S. Anderson
Laurie S. Anderson
HBHeidi G Bell
Heidi G Bell
MGMichael Gilbert
Michael Gilbert
JDJulie E Davidson
Julie E Davidson
CWChristina Winter
Christina Winter
NDNabarun Dasgupta
Nabarun Dasgupta
A multidisciplinary journal that focuses on public health and technology, public health informatics, mass media campaigns, surveillance, and innovation in public health practice and research. Also dedicated to rapid open data sharing during epidemics.

1 November 2016 in Drug and Alcohol Dependence
Verified
Journal Article
Open access
SSStevan Geoffrey Severtson
Stevan Geoffrey Severtson
Matthew S. EllisMatthew S. Ellis
Matthew S. Ellis
SKSteven P. Kurtz
Steven P. Kurtz
ARAndrew Rosenblum
Andrew Rosenblum
TCTheodore J. Cicero
Theodore J. Cicero
RDRichard C. Dart
Richard C. Dart
The development of abuse deterrent formulations is one strategy for reducing prescription opioid misuse and abuse. A putative abuse deterrent formulation of oxycodone extended release (OxyContin®) was introduced in 2010. Early reports demonstrated reduced abuse and diversion, however, an analysis of social media found 32 feasible methods to circumvent the abuse deterrent mechanism. We measured trends of diversion, abuse and street price of OxyContin to assess the durability of the initial reduction in abuse. Data from the Poison Center Program, Drug Diversion Program, Opioid Treatment Program, Survey of Key Informant Patients Program and StreetRx program of the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS®) System were used. The average quarterly rates of abuse and diversion for OxyContin were compared from before reformulation to the rate in second quarter 2015. Rates were adjusted for population using US Census data and drug availability. OxyContin abuse and diversion declined significantly each quarter after reformulation and persisted for 5 years. The rate of abuse of other opioid analgesics increased initially and then decreased, but to lesser extent than OxyContin. Abuse through both oral and non-oral routes of self-administration declined following the reformulation. The geometric mean difference in the street price of reformulated OxyContin was 36% lower than the reformulated product in the year after reformulation. Despite methods to circumvent the abuse deterrent mechanism, abuse and diversion of OxyContin decreased promptly following the introduction of a crush- and solubility- resistant formulation and continued to decrease over the subsequent 5 years.

1 August 2017 in International Journal of Drug Policy
Verified
Journal Article
Closed access
MGMichael Gilbert
Michael Gilbert
NDNabarun Dasgupta
Nabarun Dasgupta